| Detected | Trial | Change |
|---|---|---|
| 2026-06-12 | NCT06921785 Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without… |
Trial sites expanded: 217 -> 220 locations |
| 2026-06-12 | NCT04214262 Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for… |
Enrollment reduced: 480 -> 415 participants |
| 2026-06-12 | NCT04214262 Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for… |
date change Primary completion moved earlier: 2028-05-01 -> 2024-08-24 |
| 2026-06-12 | NCT04214262 Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for… |
date change Completion moved earlier: 2028-05-01 -> 2027-06-09 |
| 2026-06-12 | NCT03321643 Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual… |
date change Primary completion pushed: 2026-06-30 -> 2027-06-30 |
| 2026-06-12 | NCT03321643 Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual… |
date change Completion pushed: 2026-06-30 -> 2027-06-30 |
| 2026-06-06 | NCT05168618 Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant… |
date change Primary completion pushed: 2026-05 -> 2026-07 |
| 2026-06-05 | NCT07226999 Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in… |
Trial sites expanded: 32 -> 43 locations |
| 2026-06-03 | NCT05681039 Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With… |
overall status: "Recruiting" → "Active Not Recruiting" |
| 2026-06-02 | NCT06712355 Safety and Efficacy of BNT327, an Investigational Therapy in Combination With… |
Trial sites expanded: 138 -> 202 locations |
| 2026-05-30 | NCT05058651 Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy… |
Trial sites expanded: 245 -> 248 locations |
| 2026-05-30 | NCT07472517 DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare… |
Trial sites expanded: 232 -> 235 locations |
| 2026-05-28 | NCT06496568 A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab in… |
Primary endpoint(s) modified |
| 2026-05-28 | NCT06496568 A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab in… |
Trial arms changed: 3 -> 2 |
| 2026-05-28 | NCT06496568 A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab in… |
date change Primary completion moved earlier: 2028-09-28 -> 2027-07-21 |
| 2026-05-28 | NCT06496568 A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab in… |
date change Completion moved earlier: 2028-09-28 -> 2027-07-21 |
| 2026-05-27 | NCT07284121 A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of… |
Trial sites expanded: 88 -> 91 locations |
| 2026-05-27 | NCT04929223 A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of… |
Trial sites expanded: 76 -> 82 locations |
| 2026-05-23 | NCT04302025 A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages… |
Primary endpoint(s) modified |
| 2026-05-21 | NCT05546879 Study Investigating the Association of NP137 With Atezolizumab-Bevacizumab Combination in… |
date change Completion pushed: 2027-03-15 -> 2029-03-19 |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-06-02 | NCT07620574 Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored… | Phase 3 | Not Yet Recruiting |
| 2026-05-15 | NCT07588646 Study To Investigate The Potential DDI Between HEC585 And Pirfenidone/Nintedanib In… | Phase 1 | Completed |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 4 | |||
| NCT07059494 | Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver… | Hepatocellular Carcinoma | Recruiting |
| NCT06031233 | Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie | Oncology | Recruiting |
| NCT05689671 | Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung… | Non-Small Cell Lung Cancer Metastatic | Active, Not Recruiting |
| Phase 3 | |||
| NCT06928272 | Long Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study | Long COVID | Recruiting |
| NCT05317858 | Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care… | Brain Tumor | Recruiting |
| NCT07082842 | Confirmatory Clinical Study of HEC585 Tablets in Patients With IPF | Idiopathic Pulmonary Fibrosis (IPF) | Recruiting |
| NCT07166406 | Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients… | Advanced Hepatocellular Carcinoma | Recruiting |
| NCT05075161 | Pirfenidone to Prevent Fibrosis in Ards. | Acute Respiratory Distress Syndrome (ARDS) | Recruiting |
| NCT05862285 | A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La… | Cancer | Recruiting |
| NCT06646276 | A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed… | Extensive-Stage Small Cell Lung Cancer | Recruiting |
| NCT06712355 | Safety and Efficacy of BNT327, an Investigational Therapy in Combination With… | Extensive-stage Small-cell Lung Cancer | Recruiting |
| NCT07195695 | Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely… | Non-small Cell Lung Cancer | Recruiting |
| NCT06632327 | Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB… | Resectable Lung Non-Small Cell Carcinoma | Recruiting |
| NCT07472517 | DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare… | Small Cell Lung Cancer (SCLC) | Recruiting |
| NCT06921785 | Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without… | Hepatocellular Carcinoma | Recruiting |
| NCT05904886 | A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in… | Hepatocellular Carcinoma | Active, Not Recruiting |
| NCT04665856 | Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in… | Small Cell Lung Carcinoma | Active, Not Recruiting |
| NCT04873362 | A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and… | Breast Cancer | Active, Not Recruiting |
| NCT07461675 | Effects of Neoadjuvant Immunotherapy on Anti-tumour Immunity in Hepatocellular Carcinoma… | Hepato Cellular Carcinoma (HCC) | Not Yet Recruiting |
| NCT04102098 | A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy… | Carcinoma, Hepatocellular | Active, Not Recruiting |
| NCT04637594 | Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy | Locally Advanced Bladder Urothelial Carcinoma | Active, Not Recruiting |
| NCT04660344 | A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk… | Muscle-invasive Bladder Cancer | Active, Not Recruiting |
| NCT05047250 | A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage… | Non-Small Cell Lung Cancer | Active, Not Recruiting |
| NCT05112965 | An Extension Study in Participants Previously Enrolled in a Genentech and/or F… | Neoplasms | Active, Not Recruiting |
| NCT03148418 | A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche… | Cancer | Active, Not Recruiting |